Arvinas reports Q3 2026 results, dosing starts in new HPK1 trial
Arvinas began dosing patients in a Phase 1/2 trial of its HPK1 degrader ARV-6723 and reaffirmed plans for data from three Phase 1 programs by 2027.
SEC filing (3)
6 stories
Arvinas began dosing patients in a Phase 1/2 trial of its HPK1 degrader ARV-6723 and reaffirmed plans for data from three Phase 1 programs by 2027.
SEC filing (3)
The company finalized terms on September 29, 2026 for an offering of 36 million shares plus warrants, with proceeds aimed at funding a planned Phase 3 trial in head and neck cancer.
SEC filing (2)
The offering combines stock and warrants whose exercisability depends on a shareholder vote and the timing of a Phase 1 survival readout expected in the first half of 2027.
SEC filing
The company filed a prospectus supplement on September 29, 2026 cutting its ATM sales capacity to zero, though no shares had been sold under the program.
SEC filing
Updated results show a 36% response rate and 79% one-year survival probability, supporting plans for a Phase 3 trial starting mid-2027.
SEC filing
The board also named co-founder John Flavin Lead Independent Director as the company nears key MICVO clinical data readouts.
SEC filing